FDA Brief

Warning letters Drugs

FDA warning letter to

International Laboratories Corp

High riskIssued Mar 10, 2025Posted Mar 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

What happened

FDA inspected International Laboratories Corp's drug manufacturing facility in Samut Prakan, Thailand, from September 16 to 20, 2024. Investigators found fabricated laboratory records and investigations, deleted electronic raw data, and missing original testing and manufacturing records. FDA called the firm's October 11, 2024 response inadequate.

What FDA found

  1. Laboratory records did not include complete, reliable original data; the firm fabricated several laboratory investigations and did not keep original raw-material and finished-product test data.

    21 CFR 211.194(a)
  2. Laboratory computer systems lacked restricted access and controls, so analysts could change or delete data, and electronic raw data files were deleted or unavailable.

    21 CFR 211.68(b)
  3. The quality control unit lacked adequate oversight and the firm could not provide records for finished-product release testing, stability testing, sample collection and preparation, data review procedures, or batch production and control records.

    21 CFR 211.22(a)

What FDA wants

FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with comprehensive data-integrity and quality-unit remediation plans; it recommends an independent qualified consultant. If corrective actions cannot be completed in that time, the firm must explain the delay and provide a schedule.

Who should pay attention

  • companies that buy or distribute drugs made by this Thai manufacturer
  • brands relying on its release or stability testing
  • quality teams managing suppliers on Import Alert 66-40

This is a summary. Read the original letter on fda.gov.

International Laboratories Corp's FDA history

  1. International Laboratories Corp. Ltd.

    International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.

    High risk

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk